Sharda Cropchem Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St

July 12, 2024

Sharda Cropchem (NSE:SHARDACROP) Full Year 2024 Results

Key Financial Results

Revenue: ₹31.6b (down 22% from FY 2023).
Net income: ₹318.8m (down 91% from FY 2023).
Profit margin: 1.0% (down from 8.5% in FY 2023).
EPS: ₹3.53 (down from ₹37.90 in FY 2023).

revenue-and-expenses-breakdown — NSEI:SHARDACROP Revenue and Expenses Breakdown July 12th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sharda Cropchem EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 64%.

The primary driver behind last 12 months revenue was the Agrochemicals segment contributing a total revenue of ₹26.4b (83% of total revenue). Notably, cost of sales worth ₹23.4b amounted to 74% of total revenue thereby underscoring the impact on earnings.Explore how SHARDACROP's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India.

Performance of the Indian Chemicals industry.

The company's shares are up 4.8% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Sharda Cropchem that you should be aware of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com